A Research Study Looking at the Safety of Single Doses of ZP9830 and How it Works in the Body of Healthy Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

November 12, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Autoimmune Diseases
Interventions
DRUG

ZP9830

Participants will receive 1 single dose of ZP9830 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.

DRUG

Placebo

Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Volume will be matching the active treatment

Trial Locations (1)

2333

RECRUITING

Centre for Human Drug Research, Leiden

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Zealand Pharma

INDUSTRY